Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04725500 · ClinicalTrials.gov registry record · NA

Vector Engineering Clinical

A NA study of COPD, sponsored by Philips Clinical & Medical Affairs Global.

Completed
Registry status
NA
Development phase
42
Enrollment target
2
Study locations

NCT04725500: Completed NA study of COPD, sponsored by Philips Clinical & Medical Affairs Global.

NCT04725500 is a NA study of COPD that has completed, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 42 participants, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04725500, a NA study of COPD, has completed, sponsored by Philips Clinical & Medical Affairs Global.

COMPLETED
Registry status
NA
Development phase
42 participants
Enrollment target
2
Study locations

Study Summary

This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL). The investigator conducted a prospective, non-randomized, study on stable chronic obstructive pulmonary disease (COPD) patients that may or may not be treated currently with NIV. Patients were studied in a sleep lab on a single night with the auto - titrating EPAP that adjusts to abolish tidal EFL. The primary endpoint was to evaluate the behavior of the EPAP during the night. Additionally, a sub-group of patients used the device at home for a 2 week period. EPAP behavior was assessed during this 2 week period.

Primary Outcome

The expiratory positive airway pressure (EPAP) is the parameter that is automatically adjusted. The ventilator automatically titrates EPAP to the minimum value able to abolish expiratory flow limitation.

Conditions Studied

Interventions

  • DEVICE Auto-Titrating EPAP

Study Locations (2)

Ohio

  • Pulmonary Rehabilitation Associates - Youngstown

Pennsylvania

  • Jefferson Associates and Internal Medicine - Clairton

Trial Details

FieldValue
Enrollment Target 42 participants
Start Date 2018-10-04
Est. Completion 2020-03-03
Phase NA

What the finished NCT04725500 record still lists

NCT04725500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 2,418-participant average among 85 other COPD trials with a reported enrollment target (98% lower).

The record links to 1 condition, with COPD appearing as the primary indexed condition, and to 1 intervention - of which Auto-Titrating EPAP is the first listed.

NCT04725500 reports a single indexed study location in Ohio, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04725500 about?

NCT04725500 is a clinical study titled "Vector Engineering Clinical". This study aimed to validate a novel automatic non-invasive ventilation (NIV) mode that continuously adjusts expiratory positive airway pressure (EPAP) to the lowest value that abolishes tidal expiratory flow limitation (EFL). The investigator conducted a prospective, non-randomized, study on stable...

What is the current status of trial NCT04725500?

This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2018-10-04. Estimated completion is 2020-03-03.

What conditions does trial NCT04725500 study?

This clinical trial studies the following conditions: COPD.

What interventions are being tested in trial NCT04725500?

The interventions under investigation include: Auto-Titrating EPAP (DEVICE).

Who is sponsoring clinical trial NCT04725500?

This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04725500 being conducted?

This trial has 2 study locations across Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COPD

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04725500's enrollment target sits among peer trials

42 55th of 85 higher than 29 of 85 other COPD trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COPD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02852213 · 42 participants · Phase 1

    A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients

  • NCT03136146 · 42 participants · Phase 2

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

  • NCT03178149 · 42 participants · Phase 1

    A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

  • NCT03663530 · 42 participants · NA

    Circadian Misalignment and Energy Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04725500, the US trial registry maintained by the National Library of Medicine. NCT04725500 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.